Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trialMartin J. van den Bent, Ahmed Idbaïh, Tina Verschuere et al.|The Lancet Oncology|2018Cited by 131
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)Matthias Preusser, Wolfgang Wick, Antonio Silvani et al.|Neuro-Oncology|2021Cited by 81
Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trialLucy Brazil, Susan Short, Angela Swampillai et al.|Neuro-Oncology Advances|2020Cited by 18
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)Jaap C. Reijneveld, Martin J. van den Bent, Abigirl Machingura et al.|European Journal of Cancer|2023Cited by 13
Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.Martin J. van den Bent, Martin Klein, Marion Smits et al.|Journal of Clinical Oncology|2017Cited by 10